Hormone Replacement
Clinician-guided care to help relieve menopause symptoms, support long-term health, and help you feel like yourself again, without guesswork.
Get startedProvide information about your goals and medical history to fuel your metabolic health assessment.
.webp)
A licensed healthcare provider carefully reviews your health information and determines whether treatment is appropriate.
.webp)
Providers may recommend prescription treatments from licensed pharmacies.
.webp)
Stay connected with your clinician as your plan evolves.
Provide information about your goals and medical history to fuel your metabolic health assessment.
A licensed healthcare provider carefully reviews each case and determines whether treatment is appropriate.
Providers may recommend prescription treatments from licensed pharmacies.
Stay connected with your clinician as your plan evolves.
Many patients experience incremental changes over the first several months as care plans are adjusted and optimized.
You’ll start with a personalized plan and clear guidance. Some people notice early improvements in sleep or hot flashes.
This is when many women feel more consistent improvements —especially with hot flashes, night sweats, and sleep quality.
Your clinician can fine-tune based on your symptoms, goals, and how your body responds.
Once stable, you’ll focus on maintaining results and aligning HRT with your longevity goals (bone, heart, metabolic health).
Clinician-guided care for hormone-related symptoms, commonly perimenopause/menopause, with individualized treatment options.
Common targets include hot flashes, night sweats, sleep disruption, mood changes, and vaginal dryness. Your clinician tailors treatment to your symptoms.
Safety depends on age, medical history, and risk factors. Your clinician will discuss benefits and risks for your situation.
If you have a uterus and use systemic estrogen, progesterone is often recommended. Your clinician will specify what’s appropriate for you.
Options can include tablets, patches, creams, or vaginal therapies. The best form depends on symptoms and preferences.
Some symptoms improve within weeks; others take longer. Your clinician can adjust dose or form based on response.
HRT isn’t a weight-loss treatment. Weight changes vary and are influenced by many factors; your clinician can help with a broader plan.
Not always, but labs may help in some cases. Your clinician will advise based on history and symptoms.
Duration is individualized. Many people use the lowest effective dose with regular reassessment.
Possible effects include breast tenderness, spotting, headaches, mood changes, or skin irritation (for patches/creams).
Seek urgent care for chest pain, shortness of breath, severe headache, leg swelling, or heavy bleeding.
Yes, but it’s best to discuss tapering and symptom-management strategies with your clinician.
One of the biggest mistakes in women’s healthcare is treating menopause as a single event rather than a multi-year transition with distinct phases. A 44-year-old woman experiencing her first irregular periods and occasional hot flashes has very different needs than a 55-year-old woman who has been postmenopausal for four years and is dealing with vaginal atrophy and bone loss.
Yet many HRT programs — and many providers — apply the same approach regardless of stage. Luvo’s hormone replacement program is designed around the reality that different phases require different treatment strategies, and our 10-medication toolkit gives providers the flexibility to match treatment to phase.
Perimenopause typically begins in the mid-40s (though it can start in the late 30s) and lasts an average of 4–8 years. It’s defined by fluctuating and declining ovarian function, with estrogen levels that can swing wildly — sometimes higher than normal, sometimes crashing to postmenopausal levels, sometimes changing dramatically within a single cycle.
This hormonal chaos produces symptoms that can be confusing and unpredictable. Irregular periods are the hallmark — cycles may become shorter, longer, heavier, lighter, or skip entirely. Hot flashes may come and go. Sleep disruption often begins in earnest. Mood symptoms including anxiety, irritability, and depression are frequently reported — and are often the first symptoms women seek help for, sometimes without realizing the hormonal connection.
Brain fog and difficulty concentrating catch many perimenopausal women off guard. The cognitive changes can be alarming, particularly for women in demanding careers who rely on mental sharpness.
Because hormone levels during perimenopause are unpredictable rather than consistently low, treatment approaches need to be flexible and responsive.
Managing perimenopause requires accommodating hormonal variability rather than simply replacing a consistent deficit.
Low-dose estradiol in tablet, cream, or patch form can stabilize the hormonal fluctuations that drive symptoms. The goal isn’t to replace estrogen (the ovaries are still producing it, albeit irregularly) but to smooth out the peaks and valleys. Transdermal formulations may be particularly useful because they provide steady delivery that counterbalances the ovarian instability.
Non-hormonal options are sometimes the right starting point for perimenopausal women. Paroxetine or Desvenlafaxine can address the mood symptoms and hot flashes that are often the primary complaints during this phase, without introducing additional hormones into an already fluctuating system.
Testosterone may be relevant for perimenopausal women already experiencing libido decline and fatigue, though it’s more commonly introduced later. Luvo’s availability of testosterone in injection, tablet, and gel form means it can be added when the clinical picture warrants.
The key during perimenopause is regular reassessment. Symptoms and hormonal status evolve continuously, and treatment should evolve with them. Luvo’s ongoing provider relationship supports this adaptive approach.
After 12 months without a period, you’ve reached menopause. From this point forward, estrogen levels are consistently low and continue to decline gradually. The treatment approach shifts from managing fluctuations to addressing a stable, ongoing hormone deficit.
Systemic estradiol becomes more clearly indicated if you’re experiencing hot flashes, night sweats, sleep disruption, mood changes, or want the bone and cardiovascular protection that estrogen provides within the window of opportunity. Your Luvo provider will recommend tablets, cream, or patches based on your risk profile and preferences.
Vaginal estradiol often becomes increasingly important as GSM symptoms develop or worsen in postmenopause. Many women need both systemic and localized therapy to address the full spectrum of symptoms. Luvo’s vaginal gel and vaginal tablets provide targeted relief for urogenital concerns.
Testosterone therapy becomes more relevant as the combined effect of ovarian and adrenal testosterone decline becomes clinically significant. Many postmenopausal women who’ve been on estradiol-only HRT experience a dramatic quality-of-life improvement when testosterone is added.
Non-hormonal options remain available for women entering postmenopause who have contraindications to estrogen or who have found Paroxetine or Desvenlafaxine effective during perimenopause and wish to continue.
The transition from perimenopause through menopause and into postmenopause is a years-long journey, and your treatment needs will change along the way. A protocol that works at 46 may need significant revision by 52.
Luvo’s program is designed for this reality. Our providers don’t just prescribe a treatment and move on — they partner with you through the entire transition, adjusting medications, doses, and delivery methods as your body and symptoms evolve.
With 10 medications available, there’s always room to optimize. Starting with a non-hormonal approach and adding estradiol when appropriate. Switching from oral to transdermal if risk factors emerge. Adding vaginal estradiol as GSM develops. Incorporating testosterone when libido and energy become priorities. The flexibility is the point.
Visit Luvo’s hormone replacement program to begin your evaluation, or explore our options: estradiol tablets, cream, patches, vaginal gel, vaginal tablets, testosterone injection, tablets, gel, Paroxetine, and Desvenlafaxine.
The Women’s Health Initiative (WHI) study, published in 2002, is the most influential — and most misunderstood — study in the history of hormone replacement therapy. Its initial results, which were widely reported as showing that HRT causes breast cancer and heart disease, led to millions of women abruptly stopping treatment and a generation of providers becoming afraid to prescribe it.
The human cost of this overreaction has been enormous. Women suffered through severe menopause symptoms unnecessarily. Rates of osteoporotic fractures increased. The gap between what the evidence actually shows and what many women (and some providers) believe about HRT remains one of the biggest failures of medical communication in modern history.
This article provides a clear, evidence-based assessment of what we actually know about HRT safety in 2026.
The WHI studied two specific regimens: oral conjugated equine estrogens (Premarin) plus medroxyprogesterone acetate (Provera) in women with a uterus, and Premarin alone in women who’d had a hysterectomy.
The estrogen-only arm actually showed a decreased risk of breast cancer and no increased cardiovascular risk. It was stopped early simply because it was part of the same administrative trial as the combination arm.
The combination arm showed a small increased risk of breast cancer (8 additional cases per 10,000 women per year) and a small increased risk of cardiovascular events. However, these risks were concentrated in women who started HRT more than 10 years after menopause and were over age 60 — a population very different from the typical woman who begins HRT in her early 50s.
Critically, the WHI used oral conjugated equine estrogens (derived from horse urine, containing multiple estrogen compounds) and a synthetic progestin (medroxyprogesterone acetate) — not the bioidentical estradiol and micronized progesterone that modern HRT typically uses. Subsequent research has shown that bioidentical formulations and transdermal delivery have substantially different risk profiles.
Breast cancer risk with modern HRT is more nuanced than headlines suggest. Estrogen-only therapy does not increase breast cancer risk and may reduce it. The combination of estrogen plus micronized progesterone (the bioidentical progestogen) appears to carry less breast cancer risk than the synthetic progestins used in the WHI. When risk does exist, it’s small in absolute terms and similar to risks associated with common lifestyle factors like alcohol consumption, obesity, and sedentary behavior.
Cardiovascular risk depends heavily on timing. The “timing hypothesis” is now well-established: women who start HRT within 10 years of menopause or before age 60 show neutral or even beneficial cardiovascular effects. Women who start HRT later may face increased risk. This window of opportunity is a key consideration in Luvo’s prescribing approach.
Venous thromboembolism (blood clot) risk is increased with oral estrogen but not with transdermal estrogen. This is one of the most clinically actionable findings in modern HRT research — and it’s why Luvo offers transdermal options (cream and patches) alongside tablets.
Stroke risk shows a similar pattern to clotting risk: modestly increased with oral estrogen, not increased with transdermal delivery, and dose-dependent. Using the lowest effective dose and transdermal delivery minimizes this concern.
Luvo’s hormone replacement program is designed with risk minimization built into every level.
Formulation selection matters. Luvo uses bioidentical estradiol, not conjugated equine estrogens. The availability of transdermal options (cream and patches) allows women with clotting risk factors to avoid oral estrogen entirely.
Route-of-delivery matching means your provider recommends the delivery method based on your risk profile, not just convenience. Women with elevated thrombotic risk are guided toward transdermal options. Women with predominantly vaginal symptoms may use localized therapy with minimal systemic exposure.
Non-hormonal alternatives ensure that women who cannot safely use estrogen still have effective treatment options. Paroxetine and Desvenlafaxine provide meaningful relief without any hormonal exposure.
Timing considerations are respected. Luvo’s providers follow the evidence-based window of opportunity, recommending HRT initiation for appropriate candidates within 10 years of menopause onset.
Ongoing monitoring through regular follow-ups ensures that treatment remains appropriate and effective over time, with dose adjustments as needed.
This comprehensive, evidence-informed approach to risk management is what distinguishes Luvo from competitors that offer a limited menu of options with minimal clinical nuance. Explore the full hormone replacement program.
Estradiol is the primary estrogen your ovaries produce during your reproductive years, and it’s the gold standard for hormone replacement therapy. When your provider prescribes estradiol for menopause, you’re receiving the bioidentical hormone — chemically identical to what your body made naturally.
But how that estradiol reaches your bloodstream matters more than most women realize. Luvo offers three systemic estradiol formulations — tablets, cream, and patches — and each has distinct absorption characteristics, clinical advantages, and lifestyle implications. Understanding these differences helps you and your Luvo provider choose the option that’s genuinely right for you.
Oral estradiol tablets are the most traditional form of systemic HRT. You swallow a tablet daily, and the estradiol is absorbed through the GI tract and processed by the liver before entering the general circulation.
This “first-pass” hepatic metabolism is the defining characteristic of oral estradiol. As the hormone passes through the liver, it triggers the production of various proteins including clotting factors and sex hormone-binding globulin (SHBG). This hepatic effect is clinically relevant — it’s the reason oral estrogen carries a slightly higher risk of venous thromboembolism (blood clots) compared to transdermal routes.
That said, oral estradiol remains safe and effective for many women, particularly those at low baseline risk for clotting events. The advantages include simplicity and familiarity (it’s just a pill), well-established dosing protocols with decades of clinical data, and effective relief of hot flashes, night sweats, and other systemic symptoms.
Luvo’s estradiol tablets are bioidentical estradiol — not the conjugated equine estrogens (Premarin) used in older studies. This distinction matters for both efficacy and safety.
Estradiol cream is applied to the skin — typically the inner arm, thigh, or abdomen — where it absorbs through the dermis directly into the bloodstream, bypassing the liver entirely.
This avoidance of first-pass metabolism is the primary clinical advantage of transdermal estradiol. Without hepatic processing, transdermal estradiol does not increase clotting factor production, making it a safer option for women with elevated thrombotic risk, including those with obesity, a history of migraines with aura, or moderate cardiovascular risk factors.
Estradiol cream offers flexibility in dosing because the amount applied can be adjusted more granularly than with fixed-dose tablets or patches. This can be advantageous during the early titration phase when finding the right dose.
The practical considerations include a brief daily application routine (1–2 minutes), a short drying period before dressing, and the need to avoid washing the application site for several hours. Some women prefer the sense of control that topical application provides.
Estradiol patches are adhesive patches applied to the skin, typically on the lower abdomen or hip, and replaced once or twice weekly depending on the formulation. Like cream, patches deliver estradiol transdermally, bypassing liver metabolism.
The standout advantage of patches is steady-state hormone delivery. While oral estradiol produces peaks and troughs as the tablet is absorbed and metabolized, patches release a consistent amount of estradiol around the clock. This steady delivery can result in fewer hormonal fluctuations and more consistent symptom control.
Patches share the safety advantages of all transdermal delivery — no increased clotting risk from hepatic stimulation. They’re also the most “set-and-forget” option, requiring attention only once or twice per week.
The trade-offs include potential skin irritation at the application site (rotating sites helps), adhesion issues in humid climates or with heavy sweating, and visibility (though patches can be placed in areas covered by clothing).
For women who want effective HRT with minimal daily routine and the safest thrombotic profile, patches are often the preferred choice.
Your Luvo provider will guide this decision based on clinical factors and your preferences, but here’s a general framework.
Choose tablets if you prefer the simplicity of a daily pill, have no elevated risk for blood clots, and want a well-established, familiar treatment format.
Choose cream if you have risk factors for thrombosis, prefer flexible dosing, want transdermal safety benefits, and don’t mind a brief daily application routine.
Choose patches if you want the most consistent hormone levels, prefer a twice-weekly routine over daily, want transdermal safety with maximum convenience, and don’t have skin sensitivity to adhesives.
Many women try one formulation and switch to another based on their experience — and Luvo’s program makes switching straightforward. The goal is finding the delivery method that integrates most naturally into your life while providing optimal symptom relief.
Visit Luvo’s hormone replacement program to discuss your options with a provider, or explore each formulation: estradiol tablets, estradiol cream, and estradiol patches.
.webp)
